RUNX1 and acute myeloid leukemia: Hence, identifying mutations that carry prognostic and therapeutic impacts (including NPM1, FLT3, CEBPA, IDH1/2, DNMT3A, KIT, TP53, RUNX1 and ASXL1 mutations) has become standard in diagnostic workups for AML.1